Posted by Michael Wonder on 09 Dec 2019
Proposals for funding in the blood, alimentary and immunosuppressant therapy areas
9 December 2019 - PHARMAC is seeking feedback on proposals to widen funded access to medicines in the blood, alimentary and immunosuppressant therapy areas.
In summary, the proposals would result in the following changes from 1 March 2020:
- Ticagrelor (Brilinta) access would be widened to include prevention of thrombosis in patients who have had a neurological stent
- Budesonide capsules (Entocort CIR) access would be widened to include the treatment of patients with non-cirrhotic autoimmune hepatitis
- Etanercept (Enbrel) access would be widened to include treatment of patients with undifferentiated spondyloarthritis
- Ruxolitinib (Jakavi) access would be widened to include patients with lower risk (intermediate-1) myelofibrosis
